Invion completes study of INV103 (ala-Cpn10) in patients with systemic lupus (SLE)
Study designed to test safety and biochemical effect of materially higher doses than previous studies
Data from patients’ cells show positive effect after one month of dosing
Study supports larger, longer trials of Cpn10 in patients with autoimmune diseases
Company to focus on partnering the drug asset
Looks promising and good...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.6¢ |
Change
-0.004(4.00%) |
Mkt cap ! $8.199M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.6¢ | $5.005K | 50.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 75868 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 278199 | 3 |
View Market Depth
| Last trade - 15.03pm 31/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |